[21] This was a smaller study that enrolled 74 patients 65 years and older with NYHA class II or III heart failure (defined by the Framingham criteria) and an ejection fraction ≥40%. Background ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher ...

Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Does finerenone improve outcomes in patients withheart failure (HF) with mildly reduced or preserved ejection fraction?

UK: A secondary analysis of the FINEARTS-HF randomized clinical trial evaluated the performance of the PREDICT-HFpEF model in ...

to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fraction heart failure, with or without type 2 diabetes. AZ is building a ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.